PMID: 6108378Oct 1, 1980Paper

Anti-arrhythmic and hemodynamic effects of visken and glucagon in rhythm disorders in the acute phase of myocardial infarct

Kardiologiia
A P GolikovO B Stepura

Abstract

Combination of the beta-adrenergic blocking agent visken with glucagon in the acute period of myocardial infarction possesses higher antiarrhythmic activity with a negligible cardiodepressive effect as compared to that of isolated administration of visken and leads to a decrease in the excessive production of catecholamines and glucocorticoids in the blood.

Related Concepts

Related Feeds

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.